| Authors: |
Demetri GD; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute; Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts. gdemetri@dfci.harvard.edu., Luke JJ; Department of Medicine, The University of Chicago, Chicago, Illinois., Hollebecque A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Powderly JD 2nd; Carolina BioOncology Institute, Huntersville, North Carolina., Spira AI; Virginia Cancer Specialists, Fairfax, Virginia., Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Naumovski L; Oncology Early Development, AbbVie Inc., Redwood City, California., Chen C; Oncology Early Development, AbbVie Inc., Redwood City, California., Fang H; Oncology Early Development, AbbVie Inc., Redwood City, California., Lai DW; Oncology Early Development, AbbVie Inc., Redwood City, California., Yue H; Oncology Early Development, AbbVie Inc., Redwood City, California., Polepally AR; Oncology Early Development, AbbVie Inc., Redwood City, California., Purcell JW; Oncology Early Development, AbbVie Inc., Redwood City, California., Robinson R; Oncology Early Development, AbbVie Inc., Redwood City, California., Sharma P; Department of Immunology, MD Anderson Cancer Center, Houston, Texas., Allison JP; Department of Immunology, MD Anderson Cancer Center, Houston, Texas., Tolcher A; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas., Villalobos VM; University of Colorado - Anschutz Medical Campus, Aurora, Colorado. |
